Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012.
Tambyah PA, Hara GL, Daikos GL, Falagas ME, Mazzei T, Mouton JW, Novelli A, Chen B, Wang M, Ko WC, Li T, Fan X, Theuretzbacher U. Tambyah PA, et al. Among authors: daikos gl. J Glob Antimicrob Resist. 2013 Sep;1(3):117-122. doi: 10.1016/j.jgar.2013.04.002. Epub 2013 May 23. J Glob Antimicrob Resist. 2013. PMID: 27873621 Review.
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium. Dickstein Y, et al. Among authors: daikos gl. BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956. BMJ Open. 2016. PMID: 27098822 Free PMC article. Clinical Trial.
Action Plan to combat infections due to carbapenem-resistant, Gram-negative pathogens in acute-care hospitals in Greece.
Maltezou HC, Kontopidou F, Dedoukou X, Katerelos P, Gourgoulis GM, Tsonou P, Maragos A, Gargalianos P, Gikas A, Gogos C, Koumis I, Lelekis M, Maltezos E, Margariti G, Nikolaidis P, Pefanis A, Petrikkos G, Syrogiannopoulos G, Tsakris A, Vatopoulos A, Saroglou G, Kremastinou J, Daikos GL; Working Group for the National Action Plan to Combat Infections due to Carbapenem-Resistant, Gram-Negative Pathogens in Acute-Care Hospitals in Greece. Maltezou HC, et al. Among authors: daikos gl. J Glob Antimicrob Resist. 2014 Mar;2(1):11-16. doi: 10.1016/j.jgar.2013.06.002. Epub 2013 Aug 13. J Glob Antimicrob Resist. 2014. PMID: 27873631
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Paul M, et al. Among authors: daikos gl. Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16. Lancet Infect Dis. 2018. PMID: 29456043 Clinical Trial.
Colistin versus colistin plus meropenem for severe infections Authors' reply.
Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L. Paul M, et al. Among authors: daikos gl. Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. Lancet Infect Dis. 2018. PMID: 29695358 No abstract available.
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group. Dickstein Y, et al. Among authors: daikos gl. Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988. Clin Infect Dis. 2019. PMID: 30462182 Clinical Trial.
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. Tsuji BT, et al. Among authors: daikos gl. Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209. Pharmacotherapy. 2019. PMID: 30710469 Free PMC article.
Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.
Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, Altunin S, Bernardo M, Iossa D, Durante-Mangoni E, Antoniadou A, Skiada A, Deliolanis I, Daikos GL, Daitch V, Yahav D, Leibovici L, Rognås V, Friberg LE, Mouton JW, Paul M, Carmeli Y; AIDA Study Group. Dickstein Y, et al. Among authors: daikos gl. Clin Infect Dis. 2020 Dec 17;71(10):2599-2607. doi: 10.1093/cid/ciz1146. Clin Infect Dis. 2020. PMID: 31758195 Clinical Trial.
220 results